Market Overview

Genzyme's Once-Daily, Oral AUBAGIO Approved in Australia

Related SNY
The 4 Companies Teaming Up For A New Tool To Fight Cancer
Benzinga's M&A Chatter for Wednesday August 13, 2014
Allergan Reportedly Seeks Alternate Suitor (Fox Business)

Genzyme, a Sanofi company, (NYSE: SNY) announced today that the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO^® (teriflunomide) 14 mg as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS). The TGA approval will enable health professionals to prescribe AUBAGIO 14 mg in Australia, which is now the second country to gain marketing authorization for the treatment, following FDA approval in September.

Posted-In: News

 

Related Articles (SNY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional